Plasma granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor levels in critical illness including sepsis and septic shock: Relation to disease severity, multiple organ dysfunction, and mortality

Objective To define the circulating levels of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) during critical illness and to determine their relationship to the severity of illness as measured by the Acute Physiology and Chronic Health Evaluation (APACHE) II score, the development of multiple organ dysfunction, or mortality. Design Prospective cohort study. Setting University hospital intensive care unit. Patients A total of 82 critically ill adult patients in four clinically defined groups, namely septic shock (n = 29), sepsis without shock (n = 17), shock without sepsis (n = 22), and nonseptic, nonshock controls (n = 14). Interventions None. Measurements and Main Results During day 1 of septic shock, peak plasma levels of G-CSF, interleukin (IL)-6, and leukemia inhibitory factor (LIF), but not GM-CSF, were greater than in sepsis or shock alone (p < .001), and were correlated among themselves (rs = 0.44–0.77;p < .02) and with the APACHE II score (rs = 0.25–0.40;p = .03 to .18). G-CSF, IL-6, and LIF, and sepsis, shock, septic shock, and APACHE II scores were strongly associated with organ dysfunction or 5-day mortality by univariate analysis. However, multiple logistic regression analysis showed that only septic shock remained significantly associated with organ dysfunction and only APACHE II scores and shock with 5-day mortality. Similarly, peak G-CSF, IL-6, and LIF were poorly predictive of 30-day mortality. Conclusions Plasma levels of G-CSF, IL-6, and LIF are greatly elevated in critical illness, including septic shock, and are correlated with one another and with the severity of illness. However, they are not independently predictive of mortality, or the development of multiple organ dysfunction. GM-CSF was rarely elevated, suggesting different roles for G-CSF and GM-CSF in human septic shock.

[1]  榎本 宏之.  関節炎における Leukemia Inhibitory Factor の発現について , 1997 .

[2]  D. Dale,et al.  Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients. , 1999, The Journal of infectious diseases.

[3]  P. Kragsbjerg,et al.  Diagnostic value of blood cytokine concentrations in acute pneumonia. , 1995, Thorax.

[4]  P. Barie,et al.  Interleukin-1 contributes to increased concentrations of soluble tumor necrosis factor receptor type I in sepsis. , 1995, The Journal of infectious diseases.

[5]  C. Natanson,et al.  Cardiopulmonary effects of granulocyte colony-stimulating factor in a canine model of bacterial sepsis. , 1994, Journal of applied physiology.

[6]  D. Cullen.  Results and Costs of Intensive Care , 1977, Anesthesiology.

[7]  C. Sprung,et al.  Multiple Organ Dysfunction Score , 1996 .

[8]  François Gouin,et al.  Incidence, Risk Factors, and Outcome of Severe Sepsis and Septic Shock in Adults: A Multicenter Prospective Study in Intensive Care Units , 1995 .

[9]  C. Natanson,et al.  Leukocyte CD11b/18 antigen-directed monoclonal antibody improves early survival and decreases hypoxemia in dogs challenged with tumor necrosis factor. , 1992, The American review of respiratory disease.

[10]  A R Dunn,et al.  Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. , 1994, Blood.

[11]  J. Bennett.  The hemopoietic colony-stimulating factors: From biology to clinical applications , 1996 .

[12]  E. Pattishall,et al.  Changes in the inflammatory response of the lung during acute respiratory distress syndrome: prognostic indicators. , 1996, American journal of respiratory and critical care medicine.

[13]  W. Sibbald,et al.  Clinical Trials for the Treatment of Sepsis , 2011, Update in Intensive Care and Emergency Medicine.

[14]  S. Belknap,et al.  A Randomized Controlled Trial of Filgrastim as an Adjunct to Antibiotics for Treatment of Hospitalized Patients with Community-Acquired Pneumonia , 1998 .

[15]  W. S. Smith,et al.  Granulocyte colony-stimulating factor versus placebo in addition to penicillin G in a randomized blinded study of gram-negative pneumonia sepsis: analysis of survival and multisystem organ failure. , 1995, Blood.

[16]  J. White,et al.  Effects of granulocyte colony stimulating factor in a nonneutropenic rodent model of Escherichia coli peritonitis. , 1996, The Journal of surgical research.

[17]  J. Shellito,et al.  Phase 1 safety trial of Filgrastim (r-metHuG-CSF) in non-neutropenic patients with severe community-acquired pneumonia. , 1997, Respiratory medicine.

[18]  W. Knaus,et al.  What Determines Prognosis in Sepsis , 1995 .

[19]  E. Draper,et al.  APACHE II: A severity of disease classification system , 1985, Critical care medicine.

[20]  R. Bone,et al.  Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome , 1993, Annals of Internal Medicine.

[21]  S. Steinshamn,et al.  Cytokine mediators of septic infections in the normal and granulocytopenic host , 1993, European journal of haematology.

[22]  M. Lamy,et al.  Sepsis and serum cytokine concentrations. , 1997, Critical care medicine.

[23]  Takesada Mori,et al.  Therapeutic efficacy of granulocyte colony stimulating factor against rat cecal ligation and puncture model , 1993, Stem cells.

[24]  P Franchimont,et al.  Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. , 1992, Annals of surgery.

[25]  C. Smith,et al.  Mechanisms of neutrophil‐induced parenchymal cell injury , 1997, Journal of leukocyte biology.

[26]  S. Asano,et al.  Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. , 1989, Blood.

[27]  R. Nishinakamura,et al.  Hematopoiesis in mice lacking the entire granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 functions. , 1996, Blood.

[28]  J. Cebon,et al.  Endogenous haemopoietic growth factors in neutropenia and infection , 1994, British journal of haematology.

[29]  W. Alvord,et al.  Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans. , 1995, The Journal of infectious diseases.

[30]  F Doyon,et al.  Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. , 1995, JAMA.

[31]  P. Kragsbjerg,et al.  Dynamics of blood cytokine concentrations in patients with bacteremic infections. , 1996, Scandinavian journal of infectious diseases.

[32]  W P Sheridan,et al.  Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. , 1989, Blood.

[33]  C. Ohmann,et al.  Safety of a low-dosage Filgrastim (rhG-CSF) treatment in non-neutropenic surgical intensive care patients with an inflammatory process , 1997, Intensive Care Medicine.

[34]  R. Bone.  Guidelines for the Use of Innovative Therapies in Sepsis , 1993 .

[35]  C. Sprung,et al.  Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. , 1995, Critical care medicine.

[36]  N. Matsuura,et al.  Effect of granulocyte-macrophage colony-stimulating factor on sepsis-induced organ injury in rats. , 1994, Blood.

[37]  S. Belknap,et al.  A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. CAP Study Group. , 1998, The Journal of infectious diseases.

[38]  H. Redl,et al.  Interleukin-8 in serum and cerebrospinal fluid from patients with meningococcal disease. , 1993, The Journal of infectious diseases.

[39]  J. Pittet,et al.  Biological markers of acute lung injury: prognostic and pathogenetic significance. , 1997, American journal of respiratory and critical care medicine.

[40]  R. Gamelli,et al.  Treatment of intra-abdominal infection with granulocyte colony-stimulating factor. , 1992, The Journal of trauma.

[41]  H. Sitter,et al.  Granulocyte colony-stimulating factor prophylaxis before operation protects against lethal consequences of postoperative peritonitis. , 1994, Surgery.

[42]  M. Fink,et al.  Effect of granulocyte colony-stimulating factor on systemic and pulmonary responses to endotoxin in pigs. , 1993, The Journal of trauma.

[43]  S. Opal,et al.  Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. , 1994, JAMA.

[44]  D. Villers,et al.  Increased plasma levels of human interleukin for DA1.a cells/leukemia inhibitory factor in sepsis correlate with shock and poor prognosis. , 1995, The Journal of infectious diseases.

[45]  J. Bland,et al.  Plasma proinflammatory cytokine concentrations, Acute Physiology and Chronic Health Evaluation (APACHE) III scores and survival in patients in an intensive care unit. , 1996, Critical care medicine.

[46]  J. Hasegawa,et al.  Granulocyte colony-stimulating factor for gastrointestinal perforation in patients with leukopenia. , 1996, The Journal of trauma.

[47]  K. Kubo,et al.  Granulocyte colony-stimulating factor does not exacerbate endotoxin-induced lung injury in sheep. , 1993, The American review of respiratory disease.

[48]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[49]  J. Heath.  Colony stimulating factors: molecular and cellular biology , 1990 .

[50]  S. Akira,et al.  Interleukin-6 family of cytokines and gp130. , 1995, Blood.

[51]  R. F. Johnston,et al.  Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial , 1994 .

[52]  R. Foster,et al.  Bone Marrow Colony Stimulating Activity in Human Sera. RESULTS OF TWO INDEPENDENT SURVEYS IN BUFFALO AND MELBOURNE * , 1968, British journal of haematology.

[53]  P. Waring,et al.  Circulating leukemia inhibitory factor levels correlate with disease severity in meningococcemia. , 1994, The Journal of infectious diseases.

[54]  J. Vincent,et al.  Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. , 1993, Chest.

[55]  D. W. Maher,et al.  Differential alterations in plasma colony‐stimulating factor concentrations in meningococcaemia , 1995, Clinical and experimental immunology.

[56]  T. Shimazu,et al.  Changes in granulocyte colony-stimulating factor concentration in patients with trauma and sepsis. , 1996, The Journal of trauma.

[57]  F. Shofer,et al.  Plasma cytokine determinations in emergency department patients as a predictor of bacteremi and infectious disease severity , 1994, Critical care medicine.

[58]  J. Devière,et al.  Interleukin-10 production during septicaemia , 1994, The Lancet.

[59]  T. Kumakawa,et al.  Levels of serum granulocyte colony-stimulating factor in patients with infections. , 1990, Blood.

[60]  S Senn,et al.  Analysis of serial measurements in medical research. , 1990, BMJ.

[61]  David W. Hosmer,et al.  Applied Logistic Regression , 1991 .

[62]  Craig R. Smith,et al.  Treatment of septic shock with human monoclonal antibody HA-1A: A randomized, double-blind, placebo-controlled trial , 1995 .

[63]  R. Demling.  The modern version of adult respiratory distress syndrome. , 1995, Annual review of medicine.

[64]  A. Ishizaka,et al.  Granulocyte colony-stimulating factor does not enhance endotoxin-induced acute lung injury in guinea pigs. , 1992, The American review of respiratory disease.